Dysregulation Serum miR-19a-3p is a Diagnostic Biomarker for Asymptomatic Carotid Artery Stenosis and a Promising Predictor of Cerebral Ischemia Events

Liu, Xiaoliang; Zheng, Xiaojun; Wang, Ying; Liu, Juan

doi:10.1177/10760296211039287

Cited by 9 publications

(6 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results were observed for miR-19a-3p by Liu et al who stated that higher expression of serum miR-19a-3p (HR = 8.507, 95% CI = 2.239–32.328, p = 0.002) and degree of ICAS (HR = 3.695, 95% CI = 1.127–12.109, p = 0.031) were independent predictors for the onset of IS [ 130 ], whereas Lu et al found miR-27b an important risk factor of IS (HR = 5.067, 95% CI = 1.170–21.943, p = 0 .030) [ 131 ].…”

Section: Degree Of Carotid Plaque Patients With Asymptomatic and Symp...supporting

confidence: 85%

microRNAs Associated with Carotid Plaque Development and Vulnerability: The Clinician’s Perspective

Badacz

Przewłocki

Legutko

et al. 2022

IJMS

View full text Add to dashboard Cite

Ischemic stroke (IS) related to atherosclerosis of large arteries is one of the leading causes of mortality and disability in developed countries. Atherosclerotic internal carotid artery stenosis (ICAS) contributes to 20% of all cerebral ischemia cases. Nowadays, atherosclerosis prevention and treatment measures aim at controlling the atherosclerosis risk factors, or at the interventional (surgical or endovascular) management of mature occlusive lesions. There is a definite lack of the established circulating biomarkers which, once modulated, could prevent development of atherosclerosis, and consequently prevent the carotid-artery-related IS. Recent studies emphasize that microRNA (miRNA) are the emerging particles that could potentially play a pivotal role in this approach. There are some research studies on the association between the expression of small non-coding microRNAs with a carotid plaque development and vulnerability. However, the data remain inconsistent. In addition, all major studies on carotid atherosclerotic plaque were conducted on cell culture or animal models; very few were conducted on humans, whereas the accumulating evidence demonstrates that it cannot be automatically extrapolated to processes in humans. Therefore, this paper aims to review the current knowledge on how miRNA participate in the process of carotid plaque formation and rupture, as well as stroke occurrence. We discuss potential target miRNA that could be used as a prognostic or therapeutic tool.

show abstract

Section: Degree Of Carotid Plaque Patients With Asymptomatic and Symp...supporting

confidence: 85%

microRNAs Associated with Carotid Plaque Development and Vulnerability: The Clinician’s Perspective

Badacz

Przewłocki

Legutko

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…To support our findings, predictive role of miR-19a in future cerebral ischemic events occurrence was observed in patients with asymptomatic carotid artery stenosis (CAS), and miR-19a-3p expression was markedly higher than that in healthy subjects. Moreover, miR-19a-3p was a strong predictor of the severity of CAS [45]. Based on in vitro and in vivo analysis it was shown that miR-19a-3p directly targets and inhibits expression of IGFBP3, the gene encoding one of the insulin-like growth factors, and thus induce inflammation and apoptosis processes related to ischemia/reperfusion brain injury.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic Performance of Circulating miRNAs and Extracellular Vesicles in Acute Ischemic Stroke

Eyileten

Jakubik

Shahzadi

et al. 2022

IJMS

View full text Add to dashboard Cite

Background: Increased inflammation activates blood coagulation system, higher platelet activation plays a key role in the pathophysiology of ischemic stroke (IS). During platelet activation and aggregation process, platelets may cause increased release of several proinflammatory, and prothrombotic mediators, including microRNAs (miRNAs) and extracellular vesicles (EVs). In the current study we aimed to assess circulating miRNAs profile related to platelet function and inflammation and circulating EVs from platelets, leukocytes, and endothelial cells to analyse their diagnostic and predictive utility in patients with acute IS. Methods: The study population consisted of 28 patients with the diagnosis of the acute IS. The control group consisted of 35 age- and gender-matched patients on acetylsalicylic acid (ASA) therapy without history of stroke and/or TIA with established stable coronary artery disease (CAD) and concomitant cardiovascular risk factors. Venous blood samples were collected from the control group and patients with IS on ASA therapy (a) 24 h after onset of acute IS, (b) 7-days following index hospitalization. Flow cytometry was used to determine the concentration of circulating EVs subtypes (from platelets, leukocytes, and endothelial cells) in platelet-depleted plasma and qRT-PCR was used to determine several circulating plasma miRNAs (miR-19a-3p, miR-186-5p and let-7f). Results: Patients with high platelet reactivity (HPR, based on arachidonic acid-induced platelet aggregometry) had significantly elevated platelet-EVs (CD62+) and leukocyte-EVs (CD45+) concentration compared to patients with normal platelet reactivity at the day of 1 acute-stroke (p = 0.012, p = 0.002, respectively). Diagnostic values of baseline miRNAs and EVs were evaluated with receiver operating characteristic (ROC) curve analysis. The area under the ROC curve for miR-19a-3p was 0.755 (95% CI, 0.63–0.88) p = 0.004, for let-7f, it was 0.874 (95% CI, 0.76–0.99) p = 0.0001; platelet-EVs was 0.776 (95% CI, 0.65–0.90) p = 0.001, whereas for leukocyte-EVs, it was 0.715 (95% CI, 0.57–0.87) p = 0.008. ROC curve showed that pooling the miR-19a-3p expressions, platelet-EVs, and leukocyte-EVs concentration yielded a higher AUC than the value of each individual biomarker as AUC was 0.893 (95% CI, 0.79–0.99). Patients with moderate stroke had significantly elevated miR-19a-3p expression levels compared to patients with minor stroke at the first day of IS. (AUC: 0.867, (95% CI, 0.74–0.10) p = 0.001). Conclusion: Combining different biomarkers of processes underlying IS pathophysiology might be beneficial for early diagnosis of ischemic events. Thus, we believe that in the future circulating biomarkers might be used in the prehospital phase of IS. In particular, circulating plasma EVs and non-coding RNAs including miRNAs are interesting candidates as bearers of circulating biomarkers due to their high stability in the blood and making them highly relevant biomarkers for IS diagnostics.

show abstract

“…miR-22-3p can regulate human artery vascular smooth muscle cell proliferation and migration by targeting HMGB1, and may be therapeutic targets in the treatment of human arteriosclerosis obliterans 32) . Dysregulation Serum miR-19a-3p is a Diagnostic Biomarker for Asymptomatic Carotid Artery Stenosis and a Promising Predictor of Cerebral Ischemia Events 33) . miR-320b is a speci c serum marker for carotid atherosclerosis and vulnerable plaque, which can be used to assist in the diagnosis of cerebrovascular diseases 34) .…”

Section: Discussionmentioning

confidence: 99%

High-throughput sequencing reveals that microRNA from exosomes as potential pathogenetic factors and biomarkers of moyamoya disease

Huang

Yang

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: As a progressive cerebrovascular disease, moyamoya disease is a common cause of stroke in children and adults; however, early biomarkers and the pathogenesis of moyamoya disease remain poorly understood. Objectives: We aimed to diagnose moyamoya disease by identifying noninvasive rapid liquid diagnostic biomarkers using plasma exosomal microRNAs (miRNAs).Materials and Methods: For the first time, frozen plasma samples from moyamoya disease patients, next-generation high-throughput sequencing technologies, real-time quantitative PCR, gene ontology analysis and Kyoto Encyclopaedia of Genes and Genomes pathway analysis analyses of exosomal miRNA-related target gene functions were used to identify plasma exosomal miRNAs as potential biomarkers of moyamoya disease. The area under the curve of the receiver operating characteristic (ROC) curve was used to evaluate the sensitivity and specificity of biomarkers for predicting eventsResults: The target genes of the different expression miRNA showed that they were mainly enriched in axon guidance, regulation of the actin cytoskeleton and the MAPK signalling pathway. Ten miRNAs (miR-1306-5p, miR-196b-5p, miR-19a-3p, miR-22-3p, miR-320b, miR-34a-5p, miR-485-3p, miR-489-3p, miR-501-3p, and miR-487-3p) were found to be associated with the most sensitive and speciﬁc pathways for predicting moyamoya disease. Conclusions: Plasma exosomal miRNAs could be used to construct an accurate predictive model for improving moyamoya disease detection.

show abstract

Dysregulation Serum miR-19a-3p is a Diagnostic Biomarker for Asymptomatic Carotid Artery Stenosis and a Promising Predictor of Cerebral Ischemia Events

Cited by 9 publications

References 34 publications

microRNAs Associated with Carotid Plaque Development and Vulnerability: The Clinician’s Perspective

microRNAs Associated with Carotid Plaque Development and Vulnerability: The Clinician’s Perspective

Diagnostic Performance of Circulating miRNAs and Extracellular Vesicles in Acute Ischemic Stroke

High-throughput sequencing reveals that microRNA from exosomes as potential pathogenetic factors and biomarkers of moyamoya disease

Contact Info

Product

Resources

About